Abstract
A nasal formulation of mometasone furoate (MF) is advantageous in avoiding systemic activity characteristic of glucocorticoids when it is applied topically. To confirm antiallergic effects of this glucocorticoid formulation elaborately, we investigated whether the drug can suppress the production of IgE antibodies and related cytokines. It we showed that IgE production induced in mice immunized via intranasal route was significantly reduced when the mice were administered MF intranasally. Further, MF was effective in inhibiting production of type-2 helper T cell cytokines in vivo and in vitro. These results provide a immunopharmacological basis for clinical efficacy of this drug.
| Original language | English |
|---|---|
| Pages (from-to) | 491-500 |
| Number of pages | 10 |
| Journal | Immunopharmacology and Immunotoxicology |
| Volume | 28 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - Sep 1 2006 |
Fingerprint
ASJC Scopus subject areas
- Immunology
- Pharmacology
- Toxicology
- Health, Toxicology and Mutagenesis
Cite this
Suppressive effects of mometasone furoate on an antigen-specific IgE antibody response and production of IL-4 in mice. / Magari, Masaki; Ikeda, Mika; Asakura, Miki; Kanayama, Naoki; Ogawa, Masami; Ohmori, Hitoshi.
In: Immunopharmacology and Immunotoxicology, Vol. 28, No. 3, 01.09.2006, p. 491-500.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Suppressive effects of mometasone furoate on an antigen-specific IgE antibody response and production of IL-4 in mice
AU - Magari, Masaki
AU - Ikeda, Mika
AU - Asakura, Miki
AU - Kanayama, Naoki
AU - Ogawa, Masami
AU - Ohmori, Hitoshi
PY - 2006/9/1
Y1 - 2006/9/1
N2 - A nasal formulation of mometasone furoate (MF) is advantageous in avoiding systemic activity characteristic of glucocorticoids when it is applied topically. To confirm antiallergic effects of this glucocorticoid formulation elaborately, we investigated whether the drug can suppress the production of IgE antibodies and related cytokines. It we showed that IgE production induced in mice immunized via intranasal route was significantly reduced when the mice were administered MF intranasally. Further, MF was effective in inhibiting production of type-2 helper T cell cytokines in vivo and in vitro. These results provide a immunopharmacological basis for clinical efficacy of this drug.
AB - A nasal formulation of mometasone furoate (MF) is advantageous in avoiding systemic activity characteristic of glucocorticoids when it is applied topically. To confirm antiallergic effects of this glucocorticoid formulation elaborately, we investigated whether the drug can suppress the production of IgE antibodies and related cytokines. It we showed that IgE production induced in mice immunized via intranasal route was significantly reduced when the mice were administered MF intranasally. Further, MF was effective in inhibiting production of type-2 helper T cell cytokines in vivo and in vitro. These results provide a immunopharmacological basis for clinical efficacy of this drug.
UR - http://www.scopus.com/inward/record.url?scp=33748994820&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33748994820&partnerID=8YFLogxK
U2 - 10.1080/08923970600928155
DO - 10.1080/08923970600928155
M3 - Article
VL - 28
SP - 491
EP - 500
JO - Immunopharmacology and Immunotoxicology
JF - Immunopharmacology and Immunotoxicology
SN - 0892-3973
IS - 3
ER -